Current Osteoporosis Reports

, Volume 3, Issue 3, pp 103–110 | Cite as

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

  • Paul D. Miller


Surrogate markers in clinical medicine provide a useful means to assess therapeutic response to pharmacologic therapy in a wide range of chronic disease states. In the area of osteoporosis, the surrogate markers of change in bone mineral density (BMD) and bone turnover markers (BTM) provide the clinician with a means of assessing the biologic response to osteoporosis-specific pharmacologic agents. Increases in BMD and/or reductions in BTM can independently be correlated to reductions in vertebral and nonvertebral fracture risk. In managing osteoporosis patients, the BTM change at an earlier point of time after initiation of therapy and a change in BTM can provide earlier feed-back to the patient and clinician regarding issues such as compliance and a bone biologic response. An increase in BMD at 12 or 24 months after initiation of therapy is also evidence of an improvement in bone strength though with antiresorptive agents no change in BMD may also be associated with risk reduction within clinical trial sets. In this regard, changes in BMD and BTM are complimentary in their application to patient management.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kanis J: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Osteoporos Int 1994, 4:368–381.PubMedCrossRefGoogle Scholar
  2. 2.
    Miller PD, Hochberg M, Wehren LE, et al.: How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005, 21:545–553. This review examines why surrogate markers are valid indicators of therapeutic response in managing postmenopausal osteoporosis therapies; and, analyzes the strengths and weaknesses of the statistical methodologies used to assess changes in bone strength with the use of antiresorptive agents.PubMedCrossRefGoogle Scholar
  3. 3.
    Khosla S: Surrogates for fracture end-points in clinical trials. J Bone Miner Res 2003, 18:1146–1149.PubMedCrossRefGoogle Scholar
  4. 4.
    Watts NB, Cooper C, Linday R, et al.: Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004, 7:255–261.PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis J, Oden A, Johnell O, et al.: Uncertain future of trials in osteoporosis. Osteoporos Int 2002, 13:443–449.PubMedCrossRefGoogle Scholar
  6. 6.
    FDA position on end-points in osteoporosis clinical trials. Scholar
  7. 7.
    US Department of Health and Services: Bone health and osteoporosis: a report of the US Surgeon General. Rockville, Maryland. Department of Health and Human Services, Office of The Surgeon General. 2004.Google Scholar
  8. 8.
    Schnitzer T, Bone H, Crepasldi G, et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000, 12:1–12.Google Scholar
  9. 9.
    Brown JP, Kendler DL, McClung MR, et al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103–111.PubMedCrossRefGoogle Scholar
  10. 10.
    Miller PD, McClung M, Macovei L, et al.: Monthly oral ibandronate therapy in postmenopausal osteoporosis: one year results from the MOBILE study. J Bone Miner Res 2005, In press. This pivotal paper describes the comparator trial of monthly versus daily oral ibandronate that led to the FDA registration of this first intermittent bisphosphonate dosing.Google Scholar
  11. 11.
    Sarkar S, Reginster J-Y, Crans CG, et al.: Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004, 19:394–401.PubMedCrossRefGoogle Scholar
  12. 12.
    Delman P, Seeman E: Changes in bone mineral density explain little of the reduction in vertebral or non-vertebral fracture risk with anti-resorptive therapy. Bone 2004, 34:599–604.CrossRefGoogle Scholar
  13. 13.
    Faulkner KG: Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000, 15:183–187. This editorial examined the relationship between antiresorptive induced changes in BMD and fracture risk reduction that suggested that (in non-head-to-head studies) antiresorptive agents may reduce fracture risk similarly with little differences in BMD changes.PubMedCrossRefGoogle Scholar
  14. 14.
    Watts NB: Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results. J Reprod Med 2002, 47(Suppl 1):82–92.PubMedGoogle Scholar
  15. 15.
    Miller PD: Osteoporosis treatment outcomes: the factors that lead to the ultimate end point of osteoporosis therapies: fracture risk reduction. Endocrinologist 2003, 13(Suppl 2):S4-S9.Google Scholar
  16. 16.
    Miller PD: The treatment of osteoporosis: antiresorptive therapy. Clin Lab Med 2000, 20:603–622.PubMedGoogle Scholar
  17. 17.
    Miller PD: Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005, 27:1–16. A review of the different bisphosphonate(s) and their different effects on bone remodeling and risk reduction and the data that has led to concepts of intermittent dosing.CrossRefGoogle Scholar
  18. 18.
    Russell RGG, Croucher PI, Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999, 5(Suppl 2):S66-S80.CrossRefGoogle Scholar
  19. 19.
    Borah B, Dufrense TE, Chmielewski PA, et al.: Risedronate preserves trabecular architecture and increases bone strength in vertebrae of oophorectomized minipigs as measured by 3- dimensional microcomputed tomography. J Bone Miner Res 2002, 17:1139–1147. The first evidence suggesting that bisphosphonates increase bone strength by architectural changes that, in part, are independent of changes in bone mineral content.PubMedCrossRefGoogle Scholar
  20. 20.
    Jarvinen TLN, Sievanen H, Jokihaara J, et al.: Revival of bone strength: the bottom line. J Bone Miner Res 2005, 20:717–720.PubMedCrossRefGoogle Scholar
  21. 21.
    Turner CH, Burr DB: Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595–608.PubMedCrossRefGoogle Scholar
  22. 22.
    Burr DB, Turner CH: Biomechanics of bone. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Edited by Favus M. Washington DC: American Society for Bone and Mineral Research. 2003:58–64.Google Scholar
  23. 23.
    Burr DB: Bone material properties and mineral matrix contributions to fracture risk or age in women and men. J Musculoskelet Neuronal Interact 2002, 2:201–204.PubMedGoogle Scholar
  24. 24.
    Misof BM, Roschger P, Cosman F, et al.: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003, 88:1150–1156.PubMedCrossRefGoogle Scholar
  25. 25.
    Boivin G, Vedi S, Purdie DW, et al.: Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 2005, 36:562–567.PubMedCrossRefGoogle Scholar
  26. 26.
    Roschger P, Gupta HS, Berzlanovich A, et al.: Constant mineralization density distribution in cancellous human bone. Bone 2003, 32:316–323.PubMedCrossRefGoogle Scholar
  27. 27.
    Borah B, Ritman EL, Dufresne TE, et al.: The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005, 37:1–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Paschalis EP, Glass EV, Donley DW, Eriksen EF: Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 2005, [Epub ahead of print].Google Scholar
  29. 29.
    Paschalis EP, Shane E, Lyritis G, et al.: Bone fragility and collagen cross-links. J Bone Miner Res 2004, 19:2000–2004.PubMedCrossRefGoogle Scholar
  30. 30.
    Wasnich RD, Miller PD: Antifracture efficacy of antiresportive agents are related to changes in bone density. J Clin Endocrinol Metab 2000, 85:1–6.CrossRefGoogle Scholar
  31. 31.
    Cummings SR, Karpf DB, Harris F, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 2002, 112:281–289.PubMedCrossRefGoogle Scholar
  32. 32.
    Hochberg MC, Greenspan SL, Wasnich RD, et al.: Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586–1592.PubMedCrossRefGoogle Scholar
  33. 33.
    Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992, 11:167–178.PubMedCrossRefGoogle Scholar
  34. 34.
    Shih J, Bauer DC, Orloff J, et al.: Proportion of fracture risk reduction explained by BMD changes using Freeman’s analysis depends on choice of predictors. Osteoporos Int 2002, 13(Suppl 3):538–539.Google Scholar
  35. 35.
    Rosen CJ, Hochberg M, Bonnick S, et al.: Treatment with onceweekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, double-blind study. J Bone Miner Res 2005, 20:141–151. The head-to-head clinical trial comparing changes in BMD and BTM in postmenopausal women given weekly alendronate or risedronate.PubMedCrossRefGoogle Scholar
  36. 36.
    McClung M, Miller PD, Civetelli R, San Martin J: Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Int Med 2005, In press. The head-to-head clinical trial comparing the effects of daily (20 ώg/ day) subcutaneous teriparatide to daily (10 mg/day) alendronate on BMD and BTM in postmenopausal women.Google Scholar
  37. 37.
    Sackett DL, Straus SE, Richardson WS, et al.: Evidence Based Medicine. London: Churchill Livingstone; 2000.Google Scholar
  38. 38.
    Bonnick SL, Johnston CC Jr, Kleerekoper M, et al.: Importance of precision in bone density measurements. J Clin Densitom 2001, 4:105–110.PubMedCrossRefGoogle Scholar
  39. 39.
    Lenchick L, Leib ES, Hamdy RC, et al.: Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20–22, 2001. J Clin Densitom 2002, 5(Suppl 1):S1-S3.CrossRefGoogle Scholar
  40. 40.
    Dowd R, Recker RR, Heaney RP: Study subjects and ordinary patients. Osteoporos Int, 11:533–536.Google Scholar
  41. 41.
    Lewiecki M: Non-responders to osteoporosis therapies. J Clin Densit 2003, 6:307–314.CrossRefGoogle Scholar
  42. 42.
    Chapuy MC, Arlot ME, Duboeuf F, et al.: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637–1642.PubMedCrossRefGoogle Scholar
  43. 43.
    Delmas P, Eastell R: Percentage of 3 year vertebral and nonvertebral fracture effect explained by changes in bone resorption and BMD in postmenopausal women treated with risedronate. European Economic Congress on Osteoporosis and Osteoarthritis 2004, 5:S42.Google Scholar
  44. 44.
    Eastell R, Barton I, Hannon RA, et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051–1056. The effect of reducing bone turnover as assessed by urinary N-telopeptide on incident vertebral fracture risk reduction in postmenopausal women treated with risedronate.PubMedCrossRefGoogle Scholar
  45. 45.
    Bauer DC, Black D, Garnero P, et al.: Reduction in bone turnover predicts hip, non-spine,and vertebral fracture in alendronate treated women: the Fracture Intervention Trial. J Bone Miner Res 2004, 19:1250–1258. The effect of reducing bone turnover as assessed by bone specific alkaline phosphatase on incident vertebral fracture risk reduction in postmenopausal women treated with alendronate.PubMedCrossRefGoogle Scholar
  46. 46.
    Recker R, Lappe J, Davies KM, Heaney R: Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004, 19:1628–1633.PubMedCrossRefGoogle Scholar
  47. 47.
    Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement in bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129–2134.PubMedCrossRefGoogle Scholar
  48. 48.
    Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.PubMedCrossRefGoogle Scholar
  49. 49.
    Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate or both in mean with osteoporosis. N Engl J Med 2003, 349:1216–1226.PubMedCrossRefGoogle Scholar
  50. 50.
    Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207–1215.PubMedCrossRefGoogle Scholar
  51. 51.
    Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069–3076.PubMedCrossRefGoogle Scholar
  52. 52.
    Orwoll ES, Scheele WH, Paul S, et al.: The effect of teriparatide man parathyroid hormone (1-34)therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9–17.PubMedCrossRefGoogle Scholar
  53. 53.
    Hodsman AB, Kisiel M, Adachi JD, et al.: Histomorphometric evidence for increased bone turnover and cortical thickness without increased cortical porosity after 2 years of cyclical hPTH (1-34) therapy in women with severe osteoporosis. Bone 2000, 27:311- 318.PubMedCrossRefGoogle Scholar
  54. 54.
    Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853.PubMedCrossRefGoogle Scholar
  55. 55.
    Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide combinant human 1–34 parathyroid hormoneon cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539–543.PubMedCrossRefGoogle Scholar
  56. 56.
    Uusi-Rasi K, Semanick LM, Zanchetta JR, et al.: Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948–958. The data showing that teriparatide (rh 1–34 PTH) increases the crosssectional area of the femoral neck as measured by DXA.PubMedCrossRefGoogle Scholar
  57. 57.
    Burr DB, Hirano T, Turner CH: Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157–165.PubMedCrossRefGoogle Scholar
  58. 58.
    Cehn P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962–970. The first study to show that in groups of patient’s early changes in bone formation markers induced by teriparatide are correlated with improvements in BMD.CrossRefGoogle Scholar
  59. 59.
    Arlot M, Meunier PJ, Boivin G, et al.: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244–1253.PubMedCrossRefGoogle Scholar
  60. 60.
    Ettinger B, San Martin JA, Crans CG, et al.: Differential effects of teriparatide after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745–751.PubMedCrossRefGoogle Scholar
  61. 61.
    Deal C, Omizo M, Schwartz E, et al.: Raloxifene in combination with teriparatide reduces teriparatide-induced stimulation of bone resorption but not formation in postmenopausal women with osteoporosis. J Bone Miner Res 2004, 19(Suppl 1):S44.Google Scholar
  62. 62.
    Lindsay R, Scheele WH, Neer R, et al.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024–2030.PubMedCrossRefGoogle Scholar
  63. 63.
    Prince R, Sipos A, Hossain A, et al.: Non-vertebral fractures after PTH discontinuation. J Bone Miner Res 2005, In press.Google Scholar
  64. 64.
    van Staa TP, Geusens P, Pols HA, et al.: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005, 98:191–198.PubMedCrossRefGoogle Scholar
  65. 65.
    Van Staa TP, Laan RF, Barton IP, et al.: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224–3229.PubMedCrossRefGoogle Scholar
  66. 66.
    Maricic M, Gluck O: Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom 2004, 7:359–363.PubMedCrossRefGoogle Scholar
  67. 67.
    Miller PD, Shane E: Management of transplantation renal bone disease: interplay of bone mineral density and decisions regarding bisphosphonate use. In Medical Mangement of Kidney Transplantation. Edited by Weir MR. Philadelphia: Lippincott Williams & Wilkins; 2004:359–375.Google Scholar
  68. 68.
    Rehman Q, Lane N: Effect of glucocorticoids on bone density. Med Pediatr Oncol 2003, 41:212–216.PubMedCrossRefGoogle Scholar
  69. 69.
    Lane N: An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 2001, 27:235–253.PubMedCrossRefGoogle Scholar
  70. 70.
    Sambrook P, Lane N: Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol 2001, 15:401–413.PubMedCrossRefGoogle Scholar
  71. 71.
    Miller PD: Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int 2001, 12(Suppl 3):S3-S10.PubMedCrossRefGoogle Scholar
  72. 72.
    Weinstein RS, Chen JR, Powers CC, et al.: Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002, 109:1041–1048.PubMedCrossRefGoogle Scholar
  73. 73.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis: Recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001, 44:1496–1503. The position of the American College of Rheumatology on the prevention and treatment of GIOP.Google Scholar
  74. 74.
    Maricic M: Glucocorticoid-induced osteoporosis-treatment options and guidelines. Curr Osteo Rep 2005, 3:25–29. An excellent, accurate, and current review on treatment of GIOP.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Paul D. Miller
    • 1
  1. 1.Colorado Center for Bone ResearchLakewoodUSA

Personalised recommendations